[{"id":"8a5250ad-f3b6-42f8-b24b-850d6478ad00","acronym":"","url":"https://clinicaltrials.gov/study/NCT05274451","created_at":"2022-03-10T13:52:49.005Z","updated_at":"2024-07-02T16:35:16.777Z","phase":"Phase 1","brief_title":"A Study to Investigate LYL797 in Adults With Solid Tumors","source_id_and_acronym":"NCT05274451","lead_sponsor":"Lyell Immunopharma, Inc.","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LYL797"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-03-01"},{"id":"1b7129d0-6d4a-47c4-a842-fca0760d89ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588440","created_at":"2022-10-20T14:11:47.879Z","updated_at":"2024-07-02T16:35:27.535Z","phase":"Phase 1/2","brief_title":"A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies","source_id_and_acronym":"NCT05588440","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 overexpression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • ONCT-808"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2037","study_completion_date":" 12/01/2037","last_update_posted":"2023-11-30"},{"id":"9873bcb1-fd60-4087-b95d-ec821e1febef","acronym":"","url":"https://clinicaltrials.gov/study/NCT05748938","created_at":"2023-03-01T15:02:00.643Z","updated_at":"2024-07-02T16:35:54.515Z","phase":"Phase 1/2","brief_title":"A Study of RD14-01 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05748938","lead_sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD14-01"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/08/2023","start_date":" 02/08/2023","primary_txt":" Primary completion: 08/08/2024","primary_completion_date":" 08/08/2024","study_txt":" Completion: 02/08/2025","study_completion_date":" 02/08/2025","last_update_posted":"2023-03-01"},{"id":"5b3bda45-2924-46c8-b0d5-e8e77501cf44","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638828","created_at":"2022-12-06T15:58:00.768Z","updated_at":"2024-07-02T16:35:59.606Z","phase":"Phase 1","brief_title":"A Study of RD14-01 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05638828","lead_sponsor":"Shen Lin","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD14-01"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-12-06"}]